Edition:
India

Anavex Life Sciences reports PK and PD data from Phase 2a trial of ANAVEX2-73


Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Anavex Life Sciences Corp :Anavex Life Sciences reports PK and PD data from Phase 2a trial of ANAVEX2-73 in mild-to-moderate Alzheimer’s Disease patients.Anavex Life Sciences Corp - ‍ANAVEX2-73 demonstrates desirable PK/PD properties.Anavex Life Sciences Corp - ‍clear concentration-effect relationship between ANAVEX2-73 and study measurements​. 

Company Quote

3.53
 --
20 Sep 2019